Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 OC4.5 | DOI: 10.1530/endoabs.56.OC4.5

1Endocrinology and Nutrition Department, Research Group on Immunology and Metabolism, IRBLleida, University of Lleida, University Hospital Arnau de Vilanova, Lleida, Spain; 2Vascular and Renal Translational Research Group, IRBLleida, Unit for the Detection and The treatment of Atherothrombotic Diseases (UDETMAV&R), University of Lleida, University Hospital Arnau de Vilanova, Lleida, Spain; 3Pneumology Service, Translational Research in Respiratory Medicine, IRBLleida, University of Lleida, University Hospital Arnau de Vilanova, Lleida, Spain; 4CIBER de Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III (ISCIII), Madrid, Spain; 5Clinical Neurosciences Group, IRBLleida, Stroke Unit, University of Lleida, University Hospital Arnau de Vilanova, Lleida, Spain; 6Metabolic Pathophysiology Group, Department of Experimental Medicine, IRBLleida, University of Lleida, Lleida, Spain; 7Borges Blanques Primary Health Care Unit, Lleida, Spain; 8CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.


Background and aims: There are growing evidence supporting the deleterious effect of type 2 diabetes (T2D) on respiratory function and sleep breathing disorders. However, there is no information about the characteristics of lung function in the prediabetes stage.

Methods: We assessed pulmonary function in 3,455 non-diabetic subjects, aged between 45 and 70 years, without vascular disease nor chronic pulmonary obstructive disease from the cross-sectional study ILERVAS (ClinTrials.gov Identifier: NCT03228459). Prediabetes was defined by an HbA1c between 5.7 and 6.5%. The spirometric parameters were evaluated according to the global initiative for chronic obstructive lung disease.

Results: The entire population included 1,093 (31.6%) individuals with prediabetes and 2,362 control subjects. Subjects with prediabetes exhibited a significantly lower forced vital capacity (FVC: 93 [82;105] vs 96 [84;107] % of predicted, P<0.001), forced expiratory volume in the first second (FEV1: 95 [82;108] vs 97 [85;109] % of predicted, P=0.004) in comparison with control subjects. In addition, a higher percentage of subjects with FVC <80% (20.7% vs 16.3%) and FEV1<80% (19.7% vs 16.6%) was present among patients with prediabetes (P<0.001 for both comparisons). In the bivariate analysis, HbA1c was negatively correlated with both lung parameters (CVF: r=−0.130, P<0.001; FEV1: r=−0.097, P=0.001) in the prediabetes group; however, this relation disappeared in the control group. Finally, in the multivariate stepwise regression analysis, HbA1c independently predicted FVC (R2=0.082, β=−0.062) and FEV1 (R2=0.073, β=−0.055).

Conclusions: The negative impact of T2D in lung function seems to be present also in the prediabetes stage. Whether the preventive, diagnostic, and therapeutic measures of the ‘prediabetes lung’ should be initiated before the diagnosis of T2D needs to be evaluated in the next future.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.